(Q37013040)

17 August 2017

1 reference

title

The use of plasma-derived C1 inhibitor in the treatment of hereditary angioedema (English)

1 reference

17 August 2017

Marco Cicardi

1

1 reference

17 August 2017

Lorenza Chiara Zingale

2

1 reference

17 August 2017

Andrea Zanichelli

3

1 reference

17 August 2017

Daniela Lambertenghi Deliliers

4

1 reference

17 August 2017

Sonia Caccia

5

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 December 2007

1 reference

Expert Opinion on Pharmacotherapy

17 August 2017

published in

1 reference

17 August 2017

volume

8

1 reference

17 August 2017

issue

18

1 reference

17 August 2017

page(s)

3173-3181

1 reference

Studies on human plasma C1 inactivator-enzyme interactions. I. Mechanisms of interaction with C1s, plasmin, and trypsin

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3173

C1 inhibitor-dependent dissociation of human complement component C1 bound to immune complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3173

Contribution of Plasma Protease Inhibitors to the Inactivation of Kallikrein in Plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3173

Inactivation of kallikrein in human plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3173

Inactivation of factor XII active fragment in normal plasma. Predominant role of C-1-inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3173

Proteolytic activities of two types of mannose-binding lectin-associated serine protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3173

A true autoactivating enzyme. Structural insight into mannose-binding lectin-associated serine protease-2 activations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3173

Molecular mousetraps and the serpinopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3173

C1 inhibitor serpin domain structure reveals the likely mechanism of heparin potentiation and conformational disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3173

Human C1 inhibitor: primary structure, cDNA cloning, and chromosomal localization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3173

Replacement therapy in hereditary angioedema. Successful treatment of two patients with fresh frozen plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3173

Fresh frozen plasma for the treatment of hereditary angioedema

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3173

Viral safety of C1-inhibitor NF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3173

Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3173

Reduction in transmission of hepatitis C after the introduction of a heat-treatment step in the production of C1-inhibitor concentrate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3173

Safety and efficacy of pasteurized C1 inhibitor concentrate (Berinert P) in hereditary angioedema: a review. jean.de.serres@aventis.com

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3173

Behavior in vivo of normal and dysfunctional C1 inhibitor in normal subjects and patients with hereditary angioneurotic edema.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3173

Complement Regulatory Protein C1 Inhibitor Binds to Selectins and Interferes with Endothelial-Leukocyte Adhesion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3173

Treatment of hereditary angioedema

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3173

Long-term prophylaxis with C1-inhibitor (C1 INH) concentrate in patients with recurrent angioedema caused by hereditary and acquired C1-inhibitor deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3173

A randomized, controlled trial to study the efficacy and safety of C1 inhibitor concentrate in treating hereditary angioedema

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3173

Treatment of 193 episodes of laryngeal edema with C1 inhibitor concentrate in patients with hereditary angioedema

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3173

Clinical management of hereditary angio-oedema in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3173

Treatment with C1 inhibitor concentrate in abdominal pain attacks of patients with hereditary angioedema

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3173

Emergency treatment of acute attacks in hereditary angioedema due to C1 inhibitor deficiency: what is the evidence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3173

Hereditary angioedema managed with low-dose danazol and C1 esterase inhibitor concentrate: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3173

Self-administration of C1-inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1-inhibitor deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3173

Hereditary angioneurotic oedema: current management in pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3173

Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3173

Recent advances in the use of C1 inhibitor as a therapeutic agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3173

Hereditary angioedema: a broad review for clinicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3173

C1 inhibitor: molecular and clinical aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3173

C1 inhibitor deficiency: consensus document

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3173

Canadian 2003 International Consensus Algorithm For the Diagnosis, Therapy, and Management of Hereditary Angioedema.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3173

Antibody to C1-inhibitor in a patient receiving C1-inhibitor infusions for treatment of hereditary angioneurotic edema with systemic lupus erythematosus reacts with a normal allotype of residue 458 of C1-inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3173

Emerging infectious diseases that threaten the blood supply

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3173

The deficiency of C1 inhibitor and its treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3173

In vitro interaction of C1-inhibitor with thrombin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3173

10.1517/14656566.8.18.3173

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference